Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug development in metabolic dysfunction-associated steatohepatitis (MASH).
The partnership will harness Mursla Bio’s AI Precision Medicine Platform to generate hepatocyte-specific extracellular vesicle (h-EV) profiles from blood samples of patients with MASH and matched healthy controls.
The initial phase will focus on building high dimensional mRNA and protein datasets from h-EVs to uncover liver tissue biology in MASH. These datasets will help define mode-of-action pathways and patient stratification signatures, while enhancing Mursla Bio’s AI liver disease models developed through its MEV01 clinical study.
The company said the collaboration will also evaluate biomarker panels to identify patients most likely to benefit from the pharmaceutical company’s investigational therapy.
The same infrastructure that enabled Mursla Bio’s lead product EvoLiver to achieve FDA Breakthrough Device Designation will be used to accelerate the translation of exploratory biomarkers into regulatory-grade companion diagnostics.
Pierre Arsène, Founder and CEO of Mursla Bio, said: “This collaboration reflects the growing demand from global pharmaceutical leaders for our AI Precision Medicine Platform. As the GLP-1 revolution reshapes obesity management, MASH is rapidly emerging as the next major therapeutic focus, and the need for precise liver-specific biomarkers has never been greater.”
He added: “By profiling intact hepatocyte biology protected within the cargo of h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care. This partnership deepens our reach in hepatology, expanding on the foundation established with EvoLiver.”
MASH is a progressive form of fatty liver disease linked to obesity and type 2 diabetes. It affects 5–7% of adults globally and can lead to cirrhosis, liver failure or liver cancer.
